In vitro and in vivo binding of neuroactive steroids to the sigma-1 receptor as measured with the positron emission tomography radioligand [ 18F]FPS

Synapse

Volumn 61, Issue 7, 2007, Pages 540-546

  Waterhouse, Rikki N ^a,b,c   Chang, Raymond C ^a,b   Atuehene, Nana ^a,b   Collier, Thomas Lee ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

DHEA; Neurosteroid; Positron emission tomography; Progesterone; Testosterone

Indexed keywords

1 (3 FLUOROPROPYL) 4 [(4 CYANOPHENOXY)METHYL]PIPERIDINE F 18; PRASTERONE; PROGESTERONE; RADIOPHARMACEUTICAL AGENT; SIGMA 1 OPIATE RECEPTOR; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING;

ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; BRAIN; CELL MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORINE RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RATS; RECEPTORS, SIGMA; STEROIDS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 34248573574     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20369     Document Type: Article

References (40)

1. Bergeron R, de Montigny C, Debonnel G. 1996. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: Effects mediated via sigma receptors. J Neurosci 16:1193-1202.
2. Collier TL, O'Brien JC, Waterhouse RN. 1996. Syntheis of [F-18]-1-(3-fluoropropyl_4-(4-cyanophenoxymethylpiperidine: A potential sigma-1 receptor radioligand for PET. J Labelled Comp Radiopharm 37:785-794.
3. Damaj MI. 2001. Influence of gender and sex hormones on nicotine acute pharmacological effects in mice. J Pharmacol Experimental Therapeutics 296:132-140.
4. Debonnel G. 1993. Current hypotheses on sigma receptors and their physiological role: Possible implications in psychiatry. J Psychiatry Neurosci 18:157-172.
5. Debonnel G, Bergeron R, de Montigny C. 1996. Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D- aspartate in the CA3 region of the rat dorsal hippocampus: An effect mediated via sigma receptors. J Endocrinol 150(Suppl):S33-S42.
6. Dubrovsky BO. 2005. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuro Psychopharmacol Biol Psychiatry 29:169-192.
7. Guitart X, Codony X, Monroy X. 2004. Sigma receptors: Biology and therapeutic potential. Psychopharmacology 174:301-319.
8. Hayashi T, Su TP. 2004. Sigma-1 receptor ligands: Potential in the treatment of neuropsychiatric disorders. CNS Drugs 18:269-284.
9. Itzhak Y, Stein I. 1990. Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders. Life Sci 47:1073-1081.
10. Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V. 1996. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun 229:553-558.
11. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. 1976. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Therapeutics 197:517-532.
12. Maurice T. 2004. Neurosteroids and sigmal receptors, biochemical and behavioral relevance. Pharmacopsychiatry 37:S171-S182.
13. Maurice T, Lockhart BP. 1997. Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands. Prog Neuro Psychopharmacol Biol Psychiatry 21:69-102.
14. Maurice T, Roman FJ, Privat A. 1996. Modulation by neurosteroids of the in vivo (+)-[3H]SKF-10,047 binding to sigma 1 receptors in the mouse forebrain. J Neurosci Res 46:734-743.
15. Maurice T, Junien JL, Privat A. 1997. Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via sigma 1-receptors. Behav Brain Res 83(1-2):159-164
16. Maurice T, Phan VL, Urani A, Kamei H, Noda Y, Nabeshima T. 1999. Neuroactive neurosteroids as endogenous effectors for the sigmal (sigma1) receptor: Pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 81:125-155.
17. Maurice T, Phan VL, Urani A, Guillemain I. 2001a. Differential involvement of the sigma(1) (sigma(1)) receptor in the anti-amnesic effect of neuroactive steroids, as demonstrated using an in vivo antisense strategy in the mouse. Brit J Pharmacol 134: 1731-1741.
18. Maurice T, Urani A, Phan VL, Romieu P. 2001b. The interaction between neuroactive steroids and the sigmal receptor function: Behavioral consequences and therapeutic opportunities. Brain Res Brain Res Rev 37(1-3):116-132.
19. McCann DJ, Su TP. 1992. Tris inhibits (+)-[3H]SKF-10,047 binding to sigma receptors. Neurosci Lett 141:239-242.
20. Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K, Oda K, Sasaki T, Sakayori O, Hamamoto M, Kobayashi S, Katayama Y. 2005. Function of sigmal receptors in Parkinson's disease. Acta Neurol Scand 112:103-107.
21. Phan VL, Su TP, Privat A, Maurice T. 1999. Modulation of steroidal levels by adrenalectomy/castration and inhibition of neurosteroid synthesis enzymes affect sigmal receptor-mediated behaviour in mice. Eur J Neurosci 11:2385-2396.
22. Phan VL, Urani A, Romieu P, Maurice T. 2002. Strain differences in sigma(1) receptor-mediated behaviours are related to neurosteroid levels. Eur J Neurosci 15:1523-1534.
23. Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ. 2006. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry 163:59-66.
24. Romieu P, Martin-Fardon R, Bowen WD, Maurice T. 2003. Sigma 1 receptor-related neuroactive steroids modulate cocaine-induced reward. J Neurosci 23:3572-3576.
25. Rupprecht R, Hauser CA, Trapp T, Holsboer F. 1996. Neurosteroids: Molecular mechanisms of action and psychopharmacological significance. J Steroid Biochem Mol Biol 56:163-168.
26. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR. 2005. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 62:154-162.
27. Sofuoglu M, Babb DA, Hatsukami DK. 2001. Progesterone treatment during the early follicular phase of the menstrual cycle: Effects on smoking behavior in women. Pharmacol Biochem Behav 69(1-2): 299-304.
28. Sofuoglu M, Babb DA, Hatsukami DK. 2002. Effects of progesterone treatment on smoked cocaine response in women. Pharmacol Biochem Behav 72(1-2):431-435.
29. Sofuoglu M, Mitchell E, Kosten TR. 2004. Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacol Biochem Behav 78:699-705.
30. Stone JM, Arstad E, Erlandsson K, Waterhouse RN, Ell PJ, Pilowsky LS. 2006. [123I]TPCNE - A novel SPET tracer for the sigma-1 receptor: First human studies and in vivo haloperidol challenge. Synapse 60: 109-117.
31. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A. 2003. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 60:133-141.
32. Su TP, Hayashi T. 2003. Understanding the molecular mechanism of sigma-1 receptors: Towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 10:2073-2080.
33. Su TP, London ED, Jaffe JH. 1988. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 240:219-221.
34. van Waarde A, Buursma AR, Hospers GA, Kawamura K, Kobayashi T, Ishii K, Oda K, Ishiwata K, Vaalburg W, Elsinga PH. 2004. Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: A feasibility study. J Nucl Med 45:1939-1945.
35. 18F]1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: A selective sigma-1 receptor radioligand for PET. Nucl Med Biol 24:127-134.
36. Waterhouse RN, Lombardo I, Simpson N, Kegeles LS, Laruelle M. 2000. Evaluation of the novel sigma-1 receptor radioligand 1-(3-[F-18]Fluoropropyl)-4- [(4-cyanophenoxy)methyl]piperidine, [F-18]FPS: PET imaging studies in baboons. Neuroimage 11:S22.
37. Waterhouse RN, Slifstein M, Talbot P, Dumont F, Sultana A, Sudo Y, Narenjen R, Hackett L, Laruelle M. 2002. Validation of [F-18]1-(3-fluoropropyl)- 4-[(4-cyanomethoxy)methyl]piperidine ([F-18]FPS) as an effective PET tracer for measurement of sigma-1 receptors in the primate brain. Neuroimage 16:S6.
38. 18F]FPS) in healthy humans. Presented at the Neuroreceptor Mapping 2004, July 15-18th, Vancouver, BC, Canada.
39. Wehling M. 1994. Nongenomic actions of steriod hormones. TEM 5: 347-353.
40. Wolfe SA, De_Souza EB. 1993. Sigma and phencyclidine receptors in the brain-endocrine-immune axis. NIDA Res Monograph 133:95-123.